Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Immunization Expertise for any Antigen
Access Difficult-to-Express Antigens
Twist utilizes proprietary immunization vectors to directly express target antigens in mice, facilitating antibody discovery for challenging targets such as GPCRs and multi-spanning membrane proteins, and saving on antigen production costs and time. We can also leverage cell-based and subtractive immunization to enrich responses to cell-surface antigens.
Guidance from Antigen and Immunization Experts
The benefits of working with Twist include an experienced protein sciences team that reviews antigens and recommends critical sequence modifications before expression, optimized systems for rapid, ultra-high-yield protein production, high-level expression with appropriate post-translational modifications, and integrated antibody discovery capabilities.
Quick and Efficient Cell Line Generation
Our transient cell line generation approach allows our partners to quickly and efficiently succeed in their mAb discovery campaigns.
Rapidly Access 1000s of Off-the-Shelf Antigens
Thousands of recombinant protein antigens for popular targets are available on expedited timelines, so you can get your antibody discovery program going as quickly as possible.
Immunization Expertise for any Antigen
Access Difficult-to-Express Antigens
Twist utilizes proprietary immunization vectors to directly express target antigens in mice, facilitating antibody discovery for challenging targets such as GPCRs and multi-spanning membrane proteins, and saving on antigen production costs and time. We can also leverage cell-based and subtractive immunization to enrich responses to cell-surface antigens.
Guidance from Antigen and Immunization Experts
The benefits of working with Twist include an experienced protein sciences team that reviews antigens and recommends critical sequence modifications before expression, optimized systems for rapid, ultra-high-yield protein production, high-level expression with appropriate post-translational modifications, and integrated antibody discovery capabilities.
Quick and Efficient Cell Line Generation
Our transient cell line generation approach allows our partners to quickly and efficiently succeed in their mAb discovery campaigns.
Rapidly Access 1000s of Off-the-Shelf Antigens
Thousands of recombinant protein antigens for popular targets are available on expedited timelines, so you can get your antibody discovery program going as quickly as possible.
听听科学家们怎么说
Title
Robert Carnahan 博士
Title
Twist 是唯一能够按照我们项目所要求的数量和质量标准快速交付 DNA 的合成 DNA 供应商。我们之间的合作不仅限于提供合成基因和抗体，还进一步得到了深化，有助于我们更好地使用 Twist Biopharma 的产品，我们相信这将完善我们的抗体发现工作。
ROBERT CARNAHAN,, PHD
Vanderbilt 疫苗中心副主任
我们的平台迅速生成并验证治疗具有挑战性的癌症的新靶点。Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
JEFF GOLDBERG,, CEO
免疫疗法
联系我们
我们的抗体专家随时待命，并希望听到更多关于您的发现需求的信息。欢迎挑战性目标！
